Cargando…

Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial

BACKGROUND: SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly expressed in the lungs. The putative viral-induced inhibition of ACE2 could result in the defective degradation of bradyki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mansour, Eli, Bueno, Flávia F., de Lima-Júnior, José C., Palma, Andre, Monfort-Pires, Milena, Bombassaro, Bruna, Araujo, Eliana P., Bernardes, Ana Flavia, Ulaf, Raisa G., Nunes, Thyago A., Ribeiro, Luciana C., Falcão, Antônio Luís E., Santos, Thiago Martins, Trabasso, Plinio, Dertkigil, Rachel P., Dertkigil, Sergio S., Maia, Rafael P., Benaglia, Tatiana, Moretti, Maria Luiza, Velloso, Licio A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816150/ https://www.ncbi.nlm.nih.gov/pubmed/33472675 http://dx.doi.org/10.1186/s13063-021-05027-9

Ejemplares similares

Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19
por: Mansour, Eli, et al.
Publicado: (2021)

Plasma Angiotensin II Is Increased in Critical Coronavirus Disease 2019
por: Camargo, Rafael L., et al.
Publicado: (2022)

Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19
por: Henderson, Michael W., et al.
Publicado: (2022)

Circulating Levels of Ang/Tie2 and VEGF-a Pathway Mediators Are Associated with Clinical Severity, Endothelial Barrier Disruption and Coagulation Activation in COVID-19
por: de Moraes, Carla Roberta Peachazepi, et al.
Publicado: (2021)

Serum markers as an aid in the diagnosis of pulmonary fungal infections in AIDS patients
por: Passos, Ana Isabela Morsch, et al.
Publicado: (2017)

Simultaneous Imaging of Lung Perfusion and Glucose Metabolism in COVID-19 Pneumonia
por: Ramos, Celso Dario, et al.
Publicado: (2021)

SARS-CoV-2 receptor is co-expressed with elements of the kinin–kallikrein, renin–angiotensin and coagulation systems in alveolar cells
por: Sidarta-Oliveira, Davi, et al.
Publicado: (2020)

Identification of Fungal Pathogens by Visible Microarray System in Combination with Isothermal Gene Amplification
por: Sakai, Kanae, et al.
Publicado: (2014)

Dietary fats promote functional and structural changes in the median eminence blood/spinal fluid interface—the protective role for BDNF
por: Ramalho, Albina F., et al.
Publicado: (2018)

Development and validation of LAMP primer sets for rapid identification of Aspergillus fumigatus carrying the cyp51A TR(46) azole resistance gene
por: Trabasso, Plinio, et al.
Publicado: (2021)

Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013)

87 Treatment of Idiopathic Nonhistaminergic Angiodema with Icatibant
por: Lleonart, Ramon, et al.
Publicado: (2012)

Multiple doses of icatibant used during pregnancy
por: Kaminsky, Lauren W., et al.
Publicado: (2017)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain)
por: Takahagi, Shunsuke, et al.
Publicado: (2023)

Therapeutic trial in hereditary angioedema type III: Icatibant
por: Garro, Laila Sabino, et al.
Publicado: (2015)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Review of icatibant use in the Winnipeg Regional Health Authority
por: Cai, George, et al.
Publicado: (2020)

A20 deubiquitinase controls PGC-1α expression in the adipose tissue
por: Bombassaro, Bruna, et al.
Publicado: (2018)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Icatibant in the Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
por: Crooks, Neil H., et al.
Publicado: (2014)

164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
por: Siani, Maria Concetta, et al.
Publicado: (2012)

Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant
por: Ho, Peter, et al.
Publicado: (2014)

A Systematic Review of Automated Segmentation Methods and Public Datasets for the Lung and its Lobes and Findings on Computed Tomography Images
por: Carmo, Diedre, et al.
Publicado: (2022)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

948 Impact of active surveillance program to control VRE in a university hospital with low endemic rates
por: Cardoso, Luis Gustavo De Oliveira, et al.
Publicado: (2014)

Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study
por: Campos, Regis Albuquerque, et al.
Publicado: (2014)

Hypothalamic Microglial Activation in Obesity: A Mini-Review
por: Mendes, Natália F., et al.
Publicado: (2018)

Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma
por: Ribeiro, Luciana C., et al.
Publicado: (2021)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Asthma and COVID-19: a systematic review
por: Mendes, Natália F., et al.
Publicado: (2021)

Long‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice
por: Zanichelli, A., et al.
Publicado: (2017)

Case report of treatment with Icatibant for recurrent throat swelling due to hereditary angioedema
por: Chung, Arthur G, et al.
Publicado: (2010)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Icatibant as an early rescue therapy in hypovolemic shock with converting enzyme inhibitor treatment
por: Charbonneau, Hélène, et al.
Publicado: (2017)

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
por: Caballero, T., et al.
Publicado: (2017)

Fusarium napiforme systemic infection: case report with molecular characterization and antifungal susceptibility tests
por: de Souza, Marcela, et al.
Publicado: (2014)

THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR
por: Ratnoff, Oscar D., et al.
Publicado: (1969)

Cannot write session to /tmp/vufind_sessions/sess_f6587vrv2pphtk9cr5fl9525vv